Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03985722
Other study ID # GEIS 58
Secondary ID 2017-004771-32
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 21, 2018
Est. completion date May 5, 2024

Study information

Verified date March 2023
Source Grupo Espanol de Investigacion en Sarcomas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase I, multicentre clinical trial of olaratumab plus trabectedin in patients with advanced soft-tissue sarcoma. Olaratumab plus trabectedin could be synergistic and with a manageable toxicity profile in advanced STS. The study is a phase I, non-randomised, one-armed, multicenter trial, open-label. The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin. Primary clinical study endpoint of phase I: - Determine the maximum tolerated dose (MTD) or the recommended dose of olaratumab combined with trabectedin in advanced soft tissue sarcoma Secondary clinical study endpoints: - Objective Response Rate (ORR): ORR is defined as the number of subjects with a Best Overall Response (BOR) according to RECIST 1.1. - Progression free survival (PFS): time to progression or death from treatment initiation. - Overall survival (OS): Time from treatment initiation until death. Efficacy measured through tumor response according to Choi criteria. The evaluation criteria will be based on the identification of target lesions in baseline and their follow-up until tumor progression. - Correlation of clinical outcome with translational biomarkers. - Quality of life (QoL) measured per QLQ-C30 questionnaire of EORTC


Description:

PHASE I DESIGN The number of evaluable patients to be included in this trial is 25. However 28 patients will be enrolled considering the possibility of 3 non-evaluable cases. The dose escalation rules proceed as follows: escalating in cohorts of 3-6 patients per dose level. Three patients are treated at a given dose level. If at least 2 patients are observed to have dose-limiting toxicity (DLT), the prior dose level is defined as the maximum tolerable dosage (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients, and the process continues as above. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next cohort of 3 patients, and the process continues as above; otherwise, the prior dose level is defined as the MTD. Dose-limiting toxicity (DLT) is usually defined as cycle 1 grade 3 or above toxicity, excepting grade 3 neutropenia unaccompanied by either fever or infection. More specifically, for this clinical trial, DLT will be applied only to either of the following toxicities occurring during the first treatment cycle: Hematological toxicity: - Febrile neutropenia with documented Grade ≥3 infection or sepsis - Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia complicated by haemorrhage - Grade 4 neutropenia lasting 7 days or longer Non-hematological toxicities: Grade 3-4 events, excluding: - Nausea or vomiting without appropriate antiemetic treatment. - Grade 3 transaminitis will not be considered Dose Limiting Toxicity unless this would entail a delay in the treatment administration. This Adverse Event (AE) is well known as secondary effect of trabectedin in the first two cycles and has no clinical impact. Dose-escalation levels: LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT. LEVEL 0*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1 LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1 LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1 LEVEL 3**: Olaratumab 20 mg/kg Cycle 1, Day 1 (C1D1) and Cycle 1, Day 8 (C1D8) (induction) + Trabectedin 1.5 mg/m2 D1 Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1 * Dose starting level is 0. **In the LEVEL 3 Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8)) and then, the maintenance dose will be 15 mg/m2 for the rest of cycles. Each cycle encompasses 21 days. It is not allowed dose-escalation for one given patient. For safety reasons the first patient will be followed for 1 week before any other patient can be enrolled, given than the combination of trabectedin and olaratumab hasn't been administered to any patient so far. For the inclusion of the third patient in a given dose-level it is necessary to have all the safety information of the first cycle of the previous 2 patients included in the same dose-level. Before moving on to the next dose-level, at least three patients must have been followed during 3 weeks (1 cycle). The proposed trabectedin dose-level escalation is supported by previous phase I trials focusing on trabectedin combination. In STS, the lowest level for trabectedin was 0.9 mg/m2 for combination with doxorubicin 60 mg/m2 and showed to be active61. With other antiangiogenic agents, combination produced prolonged cytopenias. Therefore, starting level 0 uses Trabectedin 1.1mg/m2. * Tumor samples to be collected: The most recent archive tumor sample (1 block) must be donated for diagnosis confirmation and for biomarker analysis and another tumor sample after 2 cycles of olaratumab and trabectedin is also mandatory.. When feasible another tumor block should be collected after treatment. * Translational study: 1. Evaluate the signalling pathways underlying the response to the combination of olaratumab and trabectedin in formalin-fixe, paraffin-embedded (FFPE) samples, from STS patients (HTG Molecular Oncology Biomarker Panel (OBP) Assay). 2. Correlate the potential predictive biomarkers (immunomodulatory signature) of the response to olaratumab and trabectedin, with clinic results, such as progression-free survival (PFS), overall survival (OS) and response assessment. 3. To correlate the activity of olaratumab plus trabectedin with gene expression profiling in 3-methylcholanthrene (3-MCA) fibrosarcoma immunocompetent mice models. Samples: 1. FFPE samples (pre-treatment), before enrolment and after cycle 2. Both biopsies are mandatory. If the patient did not received any treatment in the last 6 months, previously to the enrolment, any biopsy taken within this period will be acceptable to the translational study. 2. When feasible, optionally for the patient, another tumor block should be collected after the end of treatment. 3. Peripheral blood samples taken at baseline, cycle 1 days 8, pre-cycle 2 day 2, pre-cycle 3 day 1 and after documented response of progression and after progression in 1 PAXgene tube and 2 BD Vacutainer® Cellular Preparation Tube (CPT)™.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 28
Est. completion date May 5, 2024
Est. primary completion date February 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients must provide written informed consent prior to performance of study specific procedures and must be willing to comply with treatment and follow-up. 2. Age: 18-80 years. 3. Histologic diagnosis of soft tissue sarcoma: liposarcoma (dedifferentiated and myxoid/round cell), leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma confirmed, before enrolment confirmation, by central pathology review by a paraffin embedded tumor tissue. 4. Metastatic/advanced disease in progression in the last 6 months. 5. Patients had previously received at least anthracyclines if clinically indicated. Previous olaratumab administration is allowed. 6. Measurable disease according to RECIST 1.1 criteria. 7. ECOG Performance Status of 0-1. 8. Adequate hepatic, renal, cardiac, and hematologic function. 9. Laboratory tests as follows: Haemoglobin >9g/dl, Absolute neutrophil count = 1,500/mm³, Platelet count = 100,000/mm³, Total Bilirubin = 1.5 mg/dL, PT= 1.5 ULN and INR = 1.5, AST and ALT = 2.5 times upper limit of normal, Creatinine = 1.5 mg/dL Calcium = 12 mg/dL and Blood glucose < 150 mg/dL, Urine protein assessment: <2+, and/or <3.5g protein/24h. 10. Left ventricular ejection fraction = 50% by echocardiogram or MUGA scan. 11. Having a central venous portal is mandatory before treatment initiation. 12. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment. Females of child-bearing potential and males and must agree to use highly effective contraceptive precautions during the trial and up to 6 months following the last dose of study drug. A highly effective method of birth control is defined as one that results in a low failure rate (that is, <1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner. Exceptions: Females not of child-bearing potential due to surgical sterilization (at least 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history or menopause. A "postmenopausal woman" is a woman meeting either of the following criteria: - spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators (SERMs), or chemotherapy - spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level >40 mIU/mL Exclusion criteria: 1. More than 2 previous lines of chemotherapy for advanced disease. Previous trabectedin not allowed. 2. Hipersensitivity to olaratumab. 3. The following histologies are not included: Ewing Sarcoma, extraskeletal osteosarcoma, extraskeletal myxoid chondrosarcoma, Kaposi's sarcoma, rhabdomyosarcoma and gastrointestinal stromal tumor (GIST). 4. Uncontrolled intercurrent illness including (not limited to): symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] III/IV), unstable angina pectoris or coronary angioplasty, or stenting within 24 weeks prior to registration, unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of NCI-CTCAE] version 5.0 Grade >= 2), known psychiatric illness that would limit study compliance, intra-cardiac defibrillators, known cardiac metastases, or abnormal cardiac valve morphology (>= Grade 3). 5. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. 6. Other disease or illness within the past 6 months, including any of the following: - Myocardial infarction - Coronary or peripheral artery bypass graft - Cerebrovascular accident or transient ischemic attack - Pulmonary embolism 7. The patient has electively planned or will require major surgery during the course of the study 8. Social situation that would preclude study compliance. 9. Prolonged QTc interval (i.e., QTc > 450 msec for males or QTc > 470 msec for females) on baseline ECG. 10. Hemorrhage = Grade 3 in the past 4 weeks. 11. Females who are pregnant or breast-feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Olaratumab and Trabectedin
Dose escalation levels: LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT. LEVEL 0*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. * Dose starting level is 0. LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1. LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1. LEVEL 3**: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1 **In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles.

Locations

Country Name City State
Spain GEIS Madrid

Sponsors (1)

Lead Sponsor Collaborator
Grupo Espanol de Investigacion en Sarcomas

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the maximum tolerated dose (MTD) or the recommended dose for phase II of Olaratumab plus Trabectedin. There will be determined the security profile for each dose level. Recruitment duration: 18 months
Secondary Objective Response Rate (ORR) Objective Response Rate (ORR): ORR is defined as the number of subjects with a Best Overall Response (BOR) according to RECIST 1.1. During recruitment and follow-up (30 months)
Secondary Progression free survival (PFS) Time to progression or death from treatment initiation During recruitment and follow-up (30 months)
Secondary Overall survival (OS) Time from treatment initiation until death During recruitment and follow-up (30 months)
Secondary Efficacy as per Choi criteria Measured through tumor response according to Choi criteria. The evaluation criteria will be based on the identification of target lesions in baseline and their follow-up until tumor progression During recruitment and follow-up (30 months)
Secondary Correlation of clinical outcome with translational biomarkers (See Translational Section) Correlation of clinical outcome with translational biomarkers (See Translational Section) During recruitment and follow-up (30 months)
Secondary QoL Measured per QLQ-C30 questionnaire of EORTC. Recruitment duration: 18 months
See also
  Status Clinical Trial Phase
Withdrawn NCT02464332 - Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery Phase 1
Completed NCT00289809 - TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients Phase 1/Phase 2
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Active, not recruiting NCT01185964 - A Study of IMC-3G3 in Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT00753688 - Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Phase 3
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT00187174 - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors Phase 1
Completed NCT03798795 - Radiomics for Tumor Grading of Soft Tissue Sarcomas.
Terminated NCT02929394 - Trabectedin Maintenance Post 1st-line in STS Phase 3
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Completed NCT00406601 - BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas Phase 2
Completed NCT00297258 - Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Phase 2
Active, not recruiting NCT06114173 - Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma Early Phase 1
Completed NCT00061659 - Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Recruiting NCT03815474 - Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT02812654 - Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment Phase 2
Completed NCT00204620 - Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS) Phase 2
Completed NCT03058406 - A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Active, not recruiting NCT02415816 - Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas N/A
Withdrawn NCT02367651 - Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma Phase 2